Forus, formerly Tandem, has secured over $160 million in a significant funding round backed by investors including Thrive Capital and General Catalyst. This capital infusion aims to accelerate the company's mission of speeding up the delivery of medical breakthroughs to patients. The funds will likely be used to enhance their platform and operations, addressing the lengthy and costly process of bringing new drugs to market.
